These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29980057)

  • 1. Apolipoprotein M in patients with chronic kidney disease.
    Sørensen IM; Bertelsen M; Freese E; Lindhard K; Ullum H; Feldt-Rasmussen B; Nielsen LB; Christoffersen C; Bro S
    Atherosclerosis; 2018 Aug; 275():304-311. PubMed ID: 29980057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of apolipoprotein M in uremic atherosclerosis.
    Bosteen MH; Madsen Svarrer EM; Bisgaard LS; Martinussen T; Madsen M; Nielsen LB; Christoffersen C; Pedersen TX
    Atherosclerosis; 2017 Oct; 265():93-101. PubMed ID: 28866363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes.
    Kumaraswamy SB; Linder A; Åkesson P; Dahlbäck B
    Crit Care; 2012 Dec; 16(2):R60. PubMed ID: 22512779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism.
    Karuna R; Park R; Othman A; Holleboom AG; Motazacker MM; Sutter I; Kuivenhoven JA; Rohrer L; Matile H; Hornemann T; Stoffel M; Rentsch KM; von Eckardstein A
    Atherosclerosis; 2011 Dec; 219(2):855-63. PubMed ID: 21944699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Shift in ApoM/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM/S1P Complex.
    Frej C; Mendez AJ; Ruiz M; Castillo M; Hughes TA; Dahlbäck B; Goldberg RB
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1194-1205. PubMed ID: 28385702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable Isotope Kinetic Study of ApoM (Apolipoprotein M).
    Croyal M; Billon-Crossouard S; Goulitquer S; Aguesse A; León L; Fall F; Chétiveaux M; Moyon T; Blanchard V; Ouguerram K; Lambert G; Nobécourt E; Krempf M
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):255-261. PubMed ID: 29146748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
    Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
    Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low plasma concentrations of apolipoprotein M are associated with disease activity and endothelial dysfunction in systemic lupus erythematosus.
    Tydén H; Lood C; Jönsen A; Gullstrand B; Kahn R; Linge P; Kumaraswamy SB; Dahlbäck B; Bengtsson AA
    Arthritis Res Ther; 2019 May; 21(1):110. PubMed ID: 31046824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate.
    Brinck JW; Thomas A; Brulhart-Meynet MC; Lauer E; Frej C; Dahlbäck B; Stenvinkel P; James RW; Frias MA
    Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29178180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased apolipoprotein M induced by lack of scavenger receptor BI is not activated via HDL-mediated cholesterol uptake in hepatocytes.
    Feng YH; Zheng L; Wei J; Yu MM; Zhang J; Luo GH; Xu N
    Lipids Health Dis; 2018 Aug; 17(1):200. PubMed ID: 30144814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes.
    Baker NL; Hammad SM; Hunt KJ; Semler A; Klein RL; Lopes-Virella MF
    Diabetes; 2022 Aug; 71(8):1795-1799. PubMed ID: 35554520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
    Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
    J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome.
    He L; Wu P; Tan L; Le B; Du W; Shen T; Wu J; Xiang Z; Hu M
    Lipids Health Dis; 2017 Sep; 16(1):167. PubMed ID: 28877724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies.
    Ahnström J; Axler O; Jauhiainen M; Salomaa V; Havulinna AS; Ehnholm C; Frikke-Schmidt R; Tybjaerg-Hansen A; Dahlbäck B
    J Lipid Res; 2008 Sep; 49(9):1912-7. PubMed ID: 18490703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of apolipoprotein M and sphingosine 1-phosphate axis in the prevention of atherosclerosis].
    Nádró B; Juhász L; Szentpéteri A; Páll D; Paragh G; Harangi M
    Orv Hetil; 2018 Feb; 159(5):168-175. PubMed ID: 29376427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.
    Ooi EM; Watts GF; Chan DC; Nielsen LB; Plomgaard P; Dahlbäck B; Barrett PH
    Atherosclerosis; 2010 May; 210(1):326-30. PubMed ID: 20031132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum high-density lipoprotein correlates with serum apolipoprotein M and A5 in obstructive sleep apnea hypopnea syndrome.
    Tan S; Liu X; Xu Y; Luo L; Zhou S; Gao Y
    Sleep Breath; 2017 Mar; 21(1):37-44. PubMed ID: 27206623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease.
    Honda H; Hirano T; Ueda M; Kojima S; Mashiba S; Hayase Y; Michihata T; Shibata T
    J Atheroscler Thromb; 2016; 23(1):81-94. PubMed ID: 26289085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoM/HDL-C and apoM/apoA-I ratios are indicators of diabetic nephropathy in healthy controls and type 2 diabetes mellitus.
    Zhang P; Gao J; Pu C; Feng G; Wang L; Huang L; Zhang Y
    Clin Chim Acta; 2017 Mar; 466():31-37. PubMed ID: 28073663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.
    Rysz-Gorzynska M; Gluba-Brzozka A; Banach M
    Curr Vasc Pharmacol; 2017; 15(2):144-151. PubMed ID: 27697068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.